Pro­to­cols: Leap re­verse merges with a fail­ing Macro­cure; Fer­ring bags rights to PhI­II sci­at­i­ca drug

Leap Ther­a­peu­tics is re­verse merg­ing its way on­to the stock ex­change. Leap signed a deal with Macro­cure to merge op­er­a­tions, with Health­Care Ven­tures in­vest­ing an ad­di­tion­al $10 mil­lion in­to their im­mune-on­col­o­gy re­search work. Macro­cure, a re­gen­er­a­tive med com­pa­ny which has been strug­gling in the wake of two big Phase III fail­ures, gets 31% of the new com­pa­ny.

Switzer­land’s Fer­ring Phar­ma­ceu­ti­cals inked a deal with Seik­a­gaku Cor­po­ra­tion grant­i­ng Fer­ring the ex­clu­sive world­wide rights (ex­clud­ing Japan) to SI-6603 (con­do­liase), a chemonu­cle­olyt­ic prod­uct in Phase III de­vel­op­ment for the treat­ment of radic­u­lar leg pain (con­di­tions that in­clude sci­at­i­ca) due to lum­bar disc her­ni­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER